Omni Bio Pharmaceutical, Inc.
Early-stage biopharmaceutical company in development of a recombinant version of a natural protein for treatment of a variety of diseases.
Omni is in preclinical development of a recombinant form of alpha-1 antitrypsin (“AAT”). AAT is an FDA-approved treatment for "AAT-deficiency," which is a market of approximately $600 million wordwide. Our recombinant form has been shown to be 40-50x more potent than native AAT. We believe our recombinant form would be a highly competitive drug to native AAT in terms of efficacy, cost to manufacture, selling price and route of administration.